-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion says phase 2 EVX-01 trial shows 86% vaccine-target immune response

PUBT·04/17/2026 19:10:17
Listen to the news
Evaxion says phase 2 EVX-01 trial shows 86% vaccine-target immune response
  • Evaxion released new phase 2 data showing its AI-Immunology platform selected vaccine targets that frequently generated tumor-specific immune responses in patients receiving personalized cancer vaccine EVX-01.
  • Results will be presented April 22, 2026, at AACR Annual Meeting in San Diego.
  • Two-year follow-up indicated immune responses remained durable, supporting potential longer-lasting treatment benefit.
  • Trial tested EVX-01 in combination with Merck’s KEYTRUDA in advanced melanoma, positioning Evaxion’s AI approach as a key driver for its personalized oncology strategy.
  • Evaxion pointed to previously reported two-year clinical results that showed a 75% objective response rate, with three-year clinical data slated for 2H 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604171510OMX_____CNEWS_EN_GNW1001176433_en) on April 17, 2026, and is solely responsible for the information contained therein.